Omeros (NASDAQ:OMER) Upgraded by ValuEngine to Strong-Buy

ValuEngine upgraded shares of Omeros (NASDAQ:OMER) from a buy rating to a strong-buy rating in a research report report published on Thursday, ValuEngine reports.

Other analysts have also recently issued research reports about the company. Cantor Fitzgerald started coverage on Omeros in a research report on Monday, May 6th. They issued an overweight rating and a $26.00 target price for the company. HC Wainwright set a $35.00 target price on Omeros and gave the stock a buy rating in a research report on Tuesday, May 28th. Zacks Investment Research raised Omeros from a sell rating to a hold rating in a research report on Saturday, August 10th. BidaskClub raised Omeros from a hold rating to a buy rating in a research report on Wednesday. Finally, Wedbush reissued a neutral rating and set a $18.00 price objective on shares of Omeros in a research report on Monday, July 15th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $25.80.

Shares of Omeros stock traded up $0.27 during midday trading on Thursday, hitting $18.85. The company’s stock had a trading volume of 7,568 shares, compared to its average volume of 487,662. The firm has a market capitalization of $908.91 million, a P/E ratio of -8.31 and a beta of 2.98. The stock has a 50-day simple moving average of $15.75 and a 200-day simple moving average of $16.59. Omeros has a 1-year low of $10.30 and a 1-year high of $27.00.

Omeros (NASDAQ:OMER) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.15. The business had revenue of $26.80 million during the quarter, compared to analyst estimates of $25.33 million. The business’s quarterly revenue was up 1476.5% on a year-over-year basis. During the same period last year, the business earned ($0.70) EPS. On average, analysts forecast that Omeros will post -1.63 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Aperio Group LLC acquired a new stake in Omeros during the second quarter valued at $49,000. Advisory Services Network LLC acquired a new stake in Omeros during the first quarter valued at $69,000. Legal & General Group Plc boosted its position in Omeros by 12.7% during the fourth quarter. Legal & General Group Plc now owns 8,370 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 945 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in Omeros by 16,167.2% during the first quarter. BNP Paribas Arbitrage SA now owns 9,923 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 9,862 shares during the last quarter. Finally, Paloma Partners Management Co acquired a new stake in Omeros during the second quarter valued at $180,000. 51.64% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Read More: Death Cross

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.